IE
EVOK

Israel Englander’s Evoke Pharma EVOK Stock Holding History

Israel Englander’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-906
Closed -$6.63K – 6056
2024
Q1 		$6.63K Buy
+906
New +$7.7K ﹤0.01% 5981
2017
Q4 		– Sell
-381
Closed -$183K – 3862
2017
Q3 		$183K Buy
+381
New +$147K ﹤0.01% 3270
2016
Q3 		– Sell
-417
Closed -$411K – 3339
2016
Q2 		$411K Hold
417
– – ﹤0.01% 2581
2016
Q1 		$306K Sell
417
-9
-2% -$4.61K ﹤0.01% 2759
2015
Q4 		$202K Buy
426
+69
+19% +$35.1K ﹤0.01% 3082
2015
Q3 		$150K Buy
+357
New +$224K ﹤0.01% 3195

Other funds holding EVOK

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Israel Englander's EVOK Position: Q2 2024 in Review

Israel Englander sold out of Evoke Pharma (EVOK) in Q2 2024, closing a stake of 906 shares — an estimated $6.63K sold.

Israel Englander first reported a position in EVOK in Q3 2015 and held it in 6 quarters. The position peaked at $411K in Q2 2016. 16 funds tracked by Wall St. Rank hold EVOK as of Q2 2024.

  • Israel Englander reported no remaining Evoke Pharma position as of Q2 2024 after selling out during the quarter.
  • Israel Englander sold 906 Evoke Pharma shares in Q2 2024, an estimated $6.63K.
  • Israel Englander first reported a position in Evoke Pharma in Q3 2015 and held it in 6 quarters.
  • Israel Englander's Evoke Pharma position peaked at $411K in Q2 2016.
  • 16 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2024.

Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.